Prevention of Akute Kidney Injury, Hearttransplant, ANP
- Registration Number
- NCT02665377
- Lead Sponsor
- Sahlgrenska University Hospital, Sweden
- Brief Summary
Prospective, blinded, placebo-controlled trial. Patients: Adult patients (\>18 years of age) undergoing de novo Htx, with a preoperative GFR \> 30ml/min, not receiving an ABO-incompatible organ with an ischemia time of \> 6 hours. A donor age \> 70 years is an exclusion criteria.
Intervention: Infusion of h-ANP fore five days, starting at the induction of anesthesia.
Outcome: Kidney function, evaluated with serum creatinine day 1-7 and kidney clearance, 4-5 Days after Htx plus after 3 and 12 months.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 86
Inclusion Criteria
- De novo Htx.
- Preoperative GFR > 30ml/min/1,73m2.
- >18 years old.
- Written consent.
Exclusion Criteria
- Multi organ transplantation or previous heart transplant.
- ECMO
- Donor age > 70 years.
- Dialysis.
- ABO-incompatible organ.
- Donor heart ischemia time > 6 tim.
- Known kidney disease.
- Other planed study within 2 mounth.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Placebo Placebo Infusion of NaCl at the same volyme as for ANP for 5 days. ANP ANP Infusion of h-ANP at dose of 50ng/kg/min fore 5 days, starting at the induction of anesthesia.
- Primary Outcome Measures
Name Time Method GFR 4-5 days after Htx 4-5 days
- Secondary Outcome Measures
Name Time Method GFR 1 year after Htx 1 year
Trial Locations
- Locations (1)
Sahlgrenska sjukhuset
🇸🇪Gothenburg, Sweden